
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates for the treatment of neuromuscular and cardiac diseases. Their lead candidate, SGT-003, has shown consistent biomarker and safety data in clinical trials, and the company is anticipating initial clinical data in the second half of 2026 and potential approval in late-2028. With a strong pipeline of potential treatments and a recent private placement that extended their cash runway to 1H28, Solid Biosciences has a positive outlook for long-term success in the gene therapy market. However, there are potential risks, including the complex regulatory pathway for gene therapies and the competitive landscape for treating rare diseases like DMD.
Bears say
Solid Biosciences is focusing primarily on gene therapy products for the treatment of neuromuscular and cardiac diseases, which faces challenges for long-term benefits and risks. Additionally, there is a risk for manufacturing delays, as well as setbacks in clinical trials and regulatory approval. Competitor companies and a potential narrower indication for approval could also impact the company's success.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares